<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20241111063665N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-03-17</date_registration>
      <primary_sponsor>self</primary_sponsor>
      <public_title>Clinical Outcomes of Low Versus Versus High Intensity Laser Therapy in the Treatment of Patients with Subacute Carpal Tunnel Syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Clinical Outcomes of Low Versus Versus High Intensity Laser Therapy in the Treatment of Patients with Subacute Carpal Tunnel Syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-08-29</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>69</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/80174</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The study utilized block randomization to allocate participants into two groups. Individuals were the unit of randomization. To ensure balance between groups, blocks of size 4 or 6 were created, with a pre-determined sequence of assignments (e.g., AABB, ABBA). A computer-based randomization tool was used to generate the random sequence, ensuring unbiased group allocation. 

The sequence was concealed, meaning participants were assigned to the next available slot in the random sequence without prior knowledge of the upcoming assignments. This allocation concealment prevented bias in group assignment. However, since the sampling method was non-probability, generalizability may be limited. The randomization tool ensured that the process was reliable and transparent, Blinding description: The study used double blinding to reduce bias. Participants were unaware of their group assignments and the specifics of the treatment they received. Similarly, assessors evaluating the outcomes were also blinded to the group allocations. This ensured that neither the participants' responses nor the assessors' evaluations were influenced by knowledge of the treatment protocols. The double-blinding helped maintain the objectivity and integrity of the study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Subacute Carpal Tunnel Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A High-Intensity Laser Therapy + Physical Therapy                                  Participants in Group A will receive High-Intensity Laser Therapy combined with Physical Therapy. The laser therapy will be delivered using a device emitting low fluency (1/6 W, 8 J/cm²). The therapy will be administered three times per week for 5 weeks. Alongside laser therapy, participants will perform four standard exercises: active and active-assisted wrist extension, active finger flexion and extension, and weight-bearing exercises on extended wrists. These treatments aim to assess the combined effects of high-intensity laser therapy and physical therapy on pain reduction and functional recovery. Intervention 2: Intervention group: B Low-intensity laser therapy group + Physical Therapy                                                    Group B will receive Low-Level Laser Therapy (LLLT) in combination with Physical Therapy. The LLLT will be delivered using high fluency (50 mW, 20 J/cm²), administered three times per week for 5 weeks. As with Group A, participants will perform the same four standard exercises, aimed at improving wrist and finger movements along with functional strength. This group will evaluate the impact of low-intensity laser therapy combined with physical therapy on recovery and pain management. Intervention 3: Intervention group: C Physical Therapy                                                                                                       Group C will receive Physical Therapy only, with no laser therapy. The same four standard exercises (active wrist extension, active finger flexion/extension, and weight-bearing wrist exercises) will be provided. This group serves as a control to compare the effectiveness of physical therapy alone against the laser therapy groups. Participants will receive no laser treatment, allowing for assessment of the placebo effect of the laser therapy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is undecided</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Arif Ali Rana</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>665-F block Central Park Housing Society Ferozpur Road Lahore</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54000</zip>
        <telephone>+92 42 34500003</telephone>
        <email>Arifalirana@gmail.com</email>
        <affiliation>University of Lahore</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Arif Ali Rana</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>665-F block Central Park Housing Society Ferozpur Road Lahore</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54000</zip>
        <telephone>+92 42 34500003</telephone>
        <email>Arifalirana@gmail.com</email>
        <affiliation>Central Park Medical College, Lahore</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age of participants 20-40 years
Individuals who have been diagnosed with carpal tunnel syndrome, regardless of gender
Based on electromyography-nerve conduction velocity (EMG-NCV) investigation, the diagnosis of mild carpal tunnel syndrome was confirmed. This involves the involvement of both sensory and motor fibers to the extent that none are absent, with a sensory and motor delay of more than 3.6 msec and 4.1 msec, respectively.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>According to an EMG-NCV investigation, there are patients with mild (sensory nerve latency &gt;3.5 ms at third digit) and severe (missing sensory or motor waves) CTS.
Patients with a history of continuous physical therapy or exercise during the previous two weeks, or taking analgesic or anti-inflammatory drugs during the week before the baseline assessment.
Hypothyroidism
Cancer
Active infection
Pulmonary disease
Acquired immunodeficiency syndrome
Associated Myopathy
Myelopathy
History of neck and/or shoulder surgery, drug abuse, corticosteroid consumption, and high-risk pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Carpal tunnel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A High-Intensity Laser Therapy + Physical Therapy                                  Participants in Group A will receive High-Intensity Laser Therapy combined with Physical Therapy. The laser therapy will be delivered using a device emitting low fluency (1/6 W, 8 J/cm²). The therapy will be administered three times per week for 5 weeks. Alongside laser therapy, participants will perform four standard exercises: active and active-assisted wrist extension, active finger flexion and extension, and weight-bearing exercises on extended wrists. These treatments aim to assess the combined effects of high-intensity laser therapy and physical therapy on pain reduction and functional recovery.</i_keyword>
      <i_keyword>Intervention group: B Low-intensity laser therapy group + Physical Therapy                                                    Group B will receive Low-Level Laser Therapy (LLLT) in combination with Physical Therapy. The LLLT will be delivered using high fluency (50 mW, 20 J/cm²), administered three times per week for 5 weeks. As with Group A, participants will perform the same four standard exercises, aimed at improving wrist and finger movements along with functional strength. This group will evaluate the impact of low-intensity laser therapy combined with physical therapy on recovery and pain management.</i_keyword>
      <i_keyword>Intervention group: C Physical Therapy                                                                                                       Group C will receive Physical Therapy only, with no laser therapy. The same four standard exercises (active wrist extension, active finger flexion/extension, and weight-bearing wrist exercises) will be provided. This group serves as a control to compare the effectiveness of physical therapy alone against the laser therapy groups. Participants will receive no laser treatment, allowing for assessment of the placebo effect of the laser therapy</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ultrasound changes. Timepoint: Before intervention and after 5 weeks of Intervention. Method of measurement: Ultrasound.</prim_outcome>
      <prim_outcome>CMAP and SNAP latencies. Timepoint: Before intervention and after 5 weeks of Intervention. Method of measurement: Nerve Conduction Studies.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pain. Timepoint: Before intervention and after 5 weeks of Intervention. Method of measurement: Visual Analogue Scale.</sec_outcome>
      <sec_outcome>Electrophysiological Changes. Timepoint: Before intervention and after 5 weeks of Intervention. Method of measurement: Nerve Conduction Studies and EMG.</sec_outcome>
      <sec_outcome>Hand Grip/ Strength. Timepoint: Before intervention and after 5 weeks of Intervention. Method of measurement: Handheld Dynamometer.</sec_outcome>
      <sec_outcome>Quality of Life. Timepoint: Before intervention and after 5 weeks of Intervention. Method of measurement: Quality of Life Scale.</sec_outcome>
      <sec_outcome>Hand Function. Timepoint: Before intervention and after 5 weeks of Intervention. Method of measurement: SF-36.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-08-22</approval_date>
        <contact_name>Research Ethics Committee (REC-Phd) FAHS, University of Lahore</contact_name>
        <contact_address>6-km Defence Road Bhobatian Chawk Lahore Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
